Current Situation and Prospect of the Application of Real-World Evidence in Health Care

摘要/Abstract

摘要： Objective To summarize the application of real-world evidence (RWE) in the medical and healthcare field of various countries, including relevant policies, application scenarios and application methods. Methods Relevant policies and application scenarios were obtained by consulting the official websites and public documents of various countries’ healthcare institutions. Systematic literature retrieval was adopted to search PubMed, EMBASE, Cochrane Library, CNKI, CBM and Wanfang databases, and all papers related to real-world study and application were included. Then, these papers were classified and analyzed by country and application method. Results and Conclusion The RWE was mainly applied to supporting the preliminary approval of a new drug, expanding drug indications, accelerating approval or supporting conditional marketing authorizations and drug safety evaluation, etc. The United Kingdom, the United States, Germany, the Netherlands, Italy, Sweden, and France admitted RWE, but they treated the data obtained from RWE with caution. After systematic literature retrieval, a total of 701 articles were obtained, including relevant studies from 36 countries, among which the United States published 264 in total. The most common study was about using real-world data (RWD) to calculate treatment-related costs, which had a total of 259 studies. Secondly, 158 articles were used for epidemiological analysis. Then, 138 articles were about establishing risk models to analyze disease risk factors. A total of 70 articles were real-world efficacy evaluation of the drug treatment schemes, 54 articles were about pharmacoeconomic evaluation with RWD as parameters. A total of 29 articles used RWD to build predictive models, and 15 articles used RWD to evaluate the health-related quality of life in patients. The application of RWE has been used widely in the medical and healthcare field of various countries. The application scenarios are gradually diversified, the application methods of RWD become mature, and the evidence quality of RWE is also improved greatly.

关键词: real-world data, real-world evidence, real-world study, medical and health care

Abstract: Objective To summarize the application of real-world evidence (RWE) in the medical and healthcare field of various countries, including relevant policies, application scenarios and application methods. Methods Relevant policies and application scenarios were obtained by consulting the official websites and public documents of various countries’ healthcare institutions. Systematic literature retrieval was adopted to search PubMed, EMBASE, Cochrane Library, CNKI, CBM and Wanfang databases, and all papers related to real-world study and application were included. Then, these papers were classified and analyzed by country and application method. Results and Conclusion The RWE was mainly applied to supporting the preliminary approval of a new drug, expanding drug indications, accelerating approval or supporting conditional marketing authorizations and drug safety evaluation, etc. The United Kingdom, the United States, Germany, the Netherlands, Italy, Sweden, and France admitted RWE, but they treated the data obtained from RWE with caution. After systematic literature retrieval, a total of 701 articles were obtained, including relevant studies from 36 countries, among which the United States published 264 in total. The most common study was about using real-world data (RWD) to calculate treatment-related costs, which had a total of 259 studies. Secondly, 158 articles were used for epidemiological analysis. Then, 138 articles were about establishing risk models to analyze disease risk factors. A total of 70 articles were real-world efficacy evaluation of the drug treatment schemes, 54 articles were about pharmacoeconomic evaluation with RWD as parameters. A total of 29 articles used RWD to build predictive models, and 15 articles used RWD to evaluate the health-related quality of life in patients. The application of RWE has been used widely in the medical and healthcare field of various countries. The application scenarios are gradually diversified, the application methods of RWD become mature, and the evidence quality of RWE is also improved greatly.

Key words: real-world data, real-world evidence, real-world study, medical and health care

Xiao Feiyi, Zhang Fang, Li Xue, Dong Li. Current Situation and Prospect of the Application of Real-World Evidence in Health Care[J]. 亚洲社会药学, 2023, 18(4): 374-386.

Xiao Feiyi, Zhang Fang, Li Xue, Dong Li. Current Situation and Prospect of the Application of Real-World Evidence in Health Care[J]. Asian Journal of Social Pharmacy, 2023, 18(4): 374-386.

[1]	Qu Yi, Wang Yuzhuo, Yuan Xiaoliang, Wang Chuang, Huang Zhe, Chen Yuwen. Experimental Design of Observational Studies in Real-World Study[J]. 亚洲社会药学, 2022, 17(3): 222-228.
[2]	Yang Lingling, Xu Fengxiang. EU Real-World Evidence Supports New Drug Research and Development Decisions and Its Implications for China[J]. 亚洲社会药学, 2021, 16(3): 197-202.
[3]	Lan Yipeng, Huang Zhe. Real-World Evidence Supporting New Drug Review and Approval in European Union and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 203-208.
[4]	Yu Zhongyi, Xu Fengxiang. The Enlightenment of EU Real-World Evidence Supporting the Inclusion of Rare Disease Drugs in Medical Insurance Decisions to China[J]. 亚洲社会药学, 2021, 16(3): 209-213.
[5]	Wang JiaoJiao, Huang Zhe. EU Real-World Evidence Supports the Expansion Indications for Drugs and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 214-218.
[6]	Wang Chao, Lian Guiyu. Research on Real-World Evidence and Application in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 219-224.
[7]	Yu Xiuna, Li Wanying, Dong Li. The Enlightenment of FDA’s “Real-World Evidence Program Framework” to China[J]. 亚洲社会药学, 2021, 16(3): 225-229.
[8]	Huang Xianqin, Chen Chuhan, Dong Li. Application of Real-World Evidence in Regulatory Decision-Making for Medical Devices[J]. 亚洲社会药学, 2021, 16(3): 230-237.
[9]	Li Longxiao, Lian Guiyu. How Real-World Evidence Supports Healthcare Decisions in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 238-241.
[10]	Wang Chuang. Research on Retrospective Studies of Real-World Study and Its Selection Bias[J]. 亚洲社会药学, 2021, 16(3): 250-255.
[11]	Wang Yuzhuo, Li Wanting, Fan Guangwei, Chen Yuwen. Discussion on the Application of Real-World Study in the Inheritance and Development of Empirical Prescriptions of Traditional Chinese Medicine[J]. 亚洲社会药学, 2021, 16(3): 256-263.
[12]	Li Jiahui, Zhao Peiyao, Yuan Xiaoliang. Research Hotspots and Trends Analysis of Real-World Data Based on Social Network Analysis and Knowledge Graph[J]. 亚洲社会药学, 2021, 16(3): 272-279.
[13]	Fu Min, Huang Zhe, Xu Fengxiang. EU Real-World Evidence Supporting Drug Regulatory Decision and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(2): 103-107.

亚洲社会药学